Basal plasma levels of copeptin are elevated in inactive inflammatory bowel disease after bowel resection

Drug Target Insights

Volumn 9, Issue , 2015, Pages 21-27

  Ohlsson, Bodil ^a,b   Melander, Olle ^a,b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Copeptin; Inflammatory bowel disease; Irritable bowel syndrome like symptoms; Neuropeptides; Precursors

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COPEPTIN; PROENKEPHALIN A; PRONEUROTENSIN; PROTACHYKININ A; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; FEMALE; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84938932829     PISSN: None     EISSN: 11773928     Source Type: Journal    
DOI: 10.4137/DTI.S26589     Document Type: Article

References (40)

1. Levite M, Chowers Y. Nerve-driven immunity: neuropeptides regulate cytokine secretion of T cells and intestinal epithelial cells in a direct, powerful and contextual manner. Ann Oncol. 2001;12:S19-S25.
2. Margolis KG, Gershon MD. Neuropeptides and inflammatory bowel disease. Curr Opin Gastroenterol. 2009;25:503-511.
3. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63:744-752.
4. Ohlsson B, Veress B, Lindgren S, Sundkvist G. Enteric ganglioneuritis and abnormal interstitial cells of Cajal; features of inflammatory bowel disease. Inflamm Bowel Dis. 2007;132:45-51.
5. Michalski CW, Autschbach F, Selvaggi F, et al. Increase in substance P precursor mRNA in noninflamed small-bowel sections in patients with Crohn's disease. Am J Surg. 2007;193:476-481.
6. ter Beek WP, Biemond I, Muller ES, van den Berg M, Lamers CB. Substance P receptor expression in patients with inflammatory bowel disease. Determination by three different techniques, i.e., storage phosphor autoradiography, RT-PCR and immunohistochemistry. Neuropeptides. 2007;41:301-306.
7. Owczarek D, Cibor D, Mach T, et al. Met-enkephalins in patients with inflammatory bowel diseases. Adv Med Sci. 2011;56:158-164.
8. Monstein HJ, Grahn N, Ohlsson B. Proenkephalin-A mRNA is widely expressed in tissues of the human gastrointestinal tract. Eur Surg Res. 2006;38:464-468.
9. Egerod KL, Engelstoft MS, Grunddal KV, et al. A major lineage of enteroendocrine cells coexpress CCK, secretin, GIP, GLP-1, PYY, and neurotensin but not somatostatin. Endocrinology. 2012;153:5782-5795.
10. Ashizuka S, Inatsu H, Inagaki-Ohara K, Kita T, Kitamura K. Adrenomedullin as a potential therapeutic agent for inflammatory bowel disease. Curr Protein Pept Sci. 2013;14:246-255.
11. Demir IE, Schäfer KH, Tieftrunk E, Friess H, Ceyhan GO. Neural plasticity in the gastrointestinal tract: chronic inflammation, neurotrophic signals, and hypersensitivity. Acta Neuropathol. 2013;125:491-509.
12. Gui X, Carraway RE, Dobner PR. Endogenous neurotensin facilitates visceral nociception and is required for stress-induced antinociception in mice and rats. Neuroscience. 2004;126:1023-1032.
13. Sobczak M, Pilarczyk A, Jonakowski M, et al. Anti-inflammatory and antinociceptive action of the dimeric enkephalin peptide biphalin in the mouse model of colitis: new potential treatment of abdominal pain associated with inflammatory bowel diseases. Peptides. 2014;60:102-106.
14. Wang GD, Wang XY, Liu S, et al. Innervation of enteric mast cells by primary spinal afferents in guinea pig and human small intestine. Am J Physiol Gastrointest Liver Physiol. 2014;307:G719-G731.
15. Monstein HJ, Truedsson M, Ryberg A, Ohlsson B. Vasopressin receptor mRNA expression in the human gastrointestinal tract. Eur Surg Res. 2008;40:34-40.
16. Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science. 1994;264:92-95.
17. Byron KL. Vasoprressin stimulates Ca2+ spiking activity in A7r5 vascular smooth muscle cells via activation of phospholipase A2. Circ Res. 1996;78:813-820.
18. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vptans. Lancet. 2008;371:1624-1632.
19. Levitan R, Mauer I. Effect of intravenous antidiuretic hormone administration on salt and water absorption from the human colon. J Lab Clin Med. 1968;72: 739-746.
20. Soergel KH, Whalen GE, Harris JA, Geenen JE. Effect of antidiuretic hormone on human small intestinal water and solute transport. J Clin Invest. 1968;47: 1071-1082.
21. Ferrier L, Serradeil-Le Gal C, Schulte AM, et al. Proinflammatory role of vasopressin through V1b receptors in hapten-induced experimental colitis in rodents: implication in IBD. Am J Physiol Gastrointest Liver Physiol. 2010;299: G1298-G1307.
22. Aardal S, Helle KB. Comparative aspects of the endocrine myocardium. Acta Physiol Scand Suppl. 1991;599:31-46.
23. Ernst A, Kohrle J, Bergmann A. Proenkephalin A 119-159, a stable proenkephalin A precursor fragment identified in human circulation. Peptides. 2006;27: 1835-1840.
24. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab. 2006;91: 4381-4386.
25. Berglund G, Eriksson KF, Israelsson B, et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med. 1996;239:489-497.
26. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden. Atherosclerosis. 2008;200:191-198.
27. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121:2102-2108.
28. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA. 2012;308:1469-1475.
29. Fenske W, Stork S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab. 2009;94:123-129.
30. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem. 2004;50:234-236.
31. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem. 2005;51:1823-1829.
32. Ernst A, Suhr J, Kohrle J, Bergmann A. Detection of stable N-terminal protachykinin A immunoreactivity in human plasma and cerebrospinal fluid. Peptides. 2008; 29:1201-1206.
33. Ernst A, Hellmich S, Bergmann A. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006;27:1787-1793.
34. Khan WI, Ghia JE. Gut hormones: emerging role in immune activation and inflammation. Clin Exp Immunol. 2010;161:19-27.
35. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36-49.
36. Wiedermann CJ, Sacerdote P, Propst A, et al. Decreased beta-endorphin content in peripheral blood mononuclear leukocytes from patients with Crohn's disease. Brain Behav Immun. 1994;8:261-269.
37. Han DM, Zhang YQ, Bai QX, Chen XQ. Assay of AVP, CRP, and LPS in leukemia. Int J Lab Hematol. 2007;29:185-189.
38. Yang J, Yang Y, Xu HT, Chen JM, Liu WY, Lin BC. Arginine vasopressin induces periaqueductal grey release of encephalin and endorphin relating to pain modulation in the rat. Regul Pept. 2007;142:29-36.
39. Keszthelyi D, Troost FJ, Jonkers DM, et al. Alterations in mucosal neuropeptides in patients with irritable bowel syndrome and ulcerative colitis in remission: a role in pain symptom generation? Eur J Pain. 2013;17:1299-1306.
40. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci. 2009; 116:257-263.